Testing

Devin Oglesbee, Ph.D., Director of the Biochemical and Molecular Genetics Laboratories at Mayo Clinic, provides an overview of the lysosomal storage disease panel, when it is appropriate to order this test, what actions the results allow you to take, and how this test improves upon previous approaches.

By Mayo Clinic Laboratories • September 6, 2017

The algorithm can be viewed here.

By Brent Westra • August 14, 2017

This algorithm can be viewed here.

By Alyssa Frank • August 11, 2017

To ensure we continue to provide the highest level of value-based reference laboratory services, Mayo Medical Laboratories will be implementing a new pathology laboratory information system on Friday, Sept. 8, 2017. View the list of orderable pathology tests included in the system upgrade.

By Andy Tofilon • August 2, 2017

An algorithm is a step-by-step procedure to guide clinicians and laboratorians in appropriate laboratory test ordering.

By Brent Westra • July 28, 2017

The algorithm can be viewed here.

By Alyssa Frank • July 28, 2017

In May 2017, Mayo Medical Laboratories announced eight brand new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • June 8, 2017

Useful For     Video Overview Clinical Information Several PSA isoforms have been identified that can further increase the specificity of PSA for prostate cancer.[...]

By Mayo Clinic Laboratories • May 9, 2017

The algorithm can be viewed here.

By Brent Westra • May 8, 2017

European Heart Journal recently highlighted Mayo Clinic's new blood test that may predict cardiovascular events in patients with or without coronary artery disease.

By Kelley Luedke • May 5, 2017

The algorithm can be viewed here.

By Alyssa Frank • April 17, 2017

Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.

By Mayo Clinic Laboratories • March 29, 2017

A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes. Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called “bad” cholesterol, but still at risk, seem to be identified.

By Mayo Clinic News Network • March 14, 2017